Actuate Therapeutics, Inc.

NasdaqGM:ACTU Stock Report

Market Cap: US$36.4m

Actuate Therapeutics Management

Management criteria checks 3/4

Actuate Therapeutics' CEO is Dan Schmitt, appointed in Mar 2015, has a tenure of 11.33 years. total yearly compensation is $2.17M, comprised of 26.3% salary and 73.7% bonuses, including company stock and options. directly owns 3.66% of the company’s shares, worth $1.33M. The average tenure of the management team and the board of directors is 4.1 years and 3.8 years respectively.

Key information

Dan Schmitt

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage26.31%
CEO tenure11.3yrs
CEO ownership3.7%
Management average tenure4.1yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Seeking Alpha • Jul 29

Actuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B Meeting

Summary Actuate Therapeutics' elraglusib combo showed strong phase 2 results in 1st-line metastatic pancreatic cancer patients, improving survival and reducing disease progression. A major catalyst is the upcoming FDA Type B pre-NDA meeting, which could allow a faster regulatory path to U.S. marketing approval or require a phase 3 trial first. Despite promising data, significant financial risks and potential dilution remain, as current cash likely won't last past Q2 2025. I rate ACTU as 'Hold' until FDA feedback clarifies the approval path; a positive outcome from it could warrant a 'Buy' upgrade. Read the full article on Seeking Alpha
Seeking Alpha • Mar 26

Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer

Summary Actuate Therapeutics' lead drug, elraglusib, shows promise in early trials for pancreatic cancer but faces challenges like solubility issues and financial instability. The company's phase 2 trial showed improved survival rates with elraglusib, but the control arm underperformed, raising questions about future phase 3 results. ACTU's financials are concerning, with only $8.6 million in cash and a high burn rate, making future funding uncertain. Despite interesting early data, the significant risks and financial challenges make ACTU a risky investment at this time. Read the full article on Seeking Alpha
Analysis Article • Feb 12

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

CEO Compensation Analysis

How has Dan Schmitt's remuneration changed compared to Actuate Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$22m

Dec 31 2025US$2mUS$570k

-US$22m

Sep 30 2025n/an/a

-US$24m

Jun 30 2025n/an/a

-US$25m

Mar 31 2025n/an/a

-US$25m

Dec 31 2024US$6mUS$400k

-US$27m

Sep 30 2024n/an/a

-US$28m

Jun 30 2024n/an/a

-US$29m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$520kUS$400k

-US$25m

Dec 31 2022US$444kUS$400k

-US$20m

Compensation vs Market: Dan's total compensation ($USD2.17M) is above average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.

CEO

Dan Schmitt (64 yo)

11.3yrs
Tenure
US$2,166,522
Compensation

Mr. Daniel M. Schmitt, also known as Dan, serves as Chief Executive Officer and President at Actuate Therapeutics, Inc. since March 2015. Mr. Schmitt served as Chief Operating Officer of Genus Oncology, LL...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Schmitt
CEO, President & Director11.3yrsUS$2.17m3.66%
$ 1.3m
Andrew Mazar
Co-Founder & COO4.1yrsUS$1.42m0.52%
$ 190.9k
Paul Lytle
Chief Financial Officer2.4yrsUS$1.01m0%
$ 0
Alan Kozikowski
Scientific Founder and Advisorno datano datano data
4.1yrs
Average Tenure
64yo
Average Age

Experienced Management: ACTU's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Schmitt
CEO, President & Director11.3yrsUS$2.17m3.66%
$ 1.3m
Todd Thomson
Independent Director3.8yrsUS$148.00k0%
$ 0
John Marshall
Member of Scientific Advisory Board3.8yrsno datano data
Lee Ellis
Member of Scientific Advisory Board3.8yrsno datano data
Roger Cohen
Member of Scientific Advisory Board3.8yrsno datano data
Daniel Zabrowski
Independent Director5.3yrsUS$160.00k0.32%
$ 116.0k
Amy Ronneberg
Independent Director1.9yrsUS$159.50k0%
$ 0
Roger Sawhney
Independent Director1.9yrsUS$159.50k0%
$ 0
Aaron Glenn Fletcher
Independent Chairman11.3yrsUS$182.00k0.32%
$ 117.2k
Jason Keyes
Independent Director1.9yrsUS$163.00k0%
$ 0
Patricia M. LoRusso
Member of Scientific Advisory Board3.8yrsno datano data
Daniel Billadeau
Member of Scientific Advisory Boardno datano datano data
3.8yrs
Average Tenure
57yo
Average Age

Experienced Board: ACTU's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 08:08
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Actuate Therapeutics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Gum-Ming LoweCraig-Hallum Capital Group LLC
Swayampakula RamakanthH.C. Wainwright & Co.